Folic acid/oral contraceptives
Executive Summary
FDA's Reproductive Health Drugs Advisory Committee will discuss the potential benefits of combining folic acid and oral contraceptives into a single product at a Dec. 15 meeting. Oral contraceptives are known to reduce the levels of folic acid, and reduced folic acid levels have been associated with neural tube defects in newborns. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m...
You may also be interested in...
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.